DURHAM, N.C., July 8, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX) , a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the presentation of three abstracts on its investigational broad-spectrum antiviral, brincidofovir (BCV, CMX001), at the 2014 World Transplant Congress (WTC) being held July 26-31, 2014 at the Moscone West Convention Center in San Francisco.
Medical Corporation (OTCBB: CONX) has been recognized for
outstanding research presented today at the American Association for
Clinical Chemistry (AACC) Annual
Meeting and Clinical Lab Expo 2014 in Chicago.
Sign-up for ZS Pharma to Present Late-Breaking Abstract Data from Phase 3 Trial of ZS-9 in State of the Art and Featured Research Session Oral Presentation at European Society of Cardiology (ESC) Congress investment picks
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.